Galderma

We are excited to announce that the European Commission has approved our novel treatment for moderate-to-severe #AtopicDermatitis and #PrurigoNodularis.    This approval provides a new treatment option for patients in Europe whose quality of life is significantly impacted by these conditions, which can cause unrelenting itch, skin lesions and significant sleep disturbance.     This milestone serves as a testament to Galderma’s commitment to driving innovation, and its purpose of #AdvancingDermatology for #EverySkinStory.    Learn more about this important milestone here: https://lnkd.in/ez93_CXf   #SkinScienceByGalderma 

“𝐒𝐤𝐢𝐧 𝐢𝐬 𝐭𝐢𝐞𝐝 𝐭𝐨 𝐥𝐨𝐭𝐬 𝐨𝐟 𝐯𝐚𝐫𝐢𝐚𝐛𝐥𝐞𝐬 – 𝐡𝐨𝐫𝐦𝐨𝐧𝐞𝐬, 𝐧𝐮𝐭𝐫𝐢𝐭𝐢𝐨𝐧, 𝐞𝐱𝐞𝐫𝐜𝐢𝐬𝐞. 𝐈 𝐭𝐚𝐤𝐞 𝐚𝐥𝐥 𝐨𝐟 𝐭𝐡𝐞𝐬𝐞 𝐢𝐧𝐭𝐨 𝐚𝐜𝐜𝐨𝐮𝐧𝐭 𝐰𝐡𝐞𝐧 𝐝𝐞𝐬𝐢𝐠𝐧𝐢𝐧𝐠 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐩𝐥𝐚𝐧𝐬 𝐟𝐨𝐫 𝐦𝐲 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬.” As the founder of the Anti-aging Sciences & Cosmetics Institute in Manila, Philippines, Dr. Cri Puyat takes a holistic approach to beauty. By leveraging her background in stem cell science, her aesthetic techniques focus on harnessing the body’s natural abilities. In our latest episode of Beauty x Medicine, our CEO Flemming Ornskov, MD, MPH, speaks with Dr. Puyat about her predictions for a synergetic, multifaceted future of aesthetics. Watch their discussion now. #AdvancingDermatology #BeautyXMedicine

Our mission at Galderma is to #AdvanceDermatology for every skin story, and we understand the importance of listening to and learning from the dermatology community in order to achieve this goal.    With around 100 healthcare professionals from North America and Europe in attendance, our latest SKIN medical summit in Berlin was a unique opportunity to deep dive into the needs of patients living with #AtopicDermatitis and #PrurigoNodularis and the realities of treating these two skin conditions.    Thank you to our faculty who expertly led our sessions and all attendees for your enthusiastic participation and valuable insights!    2025 will be an exciting year for Galderma in Therapeutic Dermatology and we look forward to more opportunities to learn and engage with the medical community – next up; #AAD2025 from March 5-9! 

New Campaign Alert! In today's world, sensitivity is universal, whether it's from daily stress, cultural conversations or even missing out on important moments. When we learned that Lil Wayne would not be headlining the Super Bowl halftime show in his hometown, we recognized a moment of real sensitivity. That's why Cetaphil is embracing this moment of cultural sensitivity with its latest campaign launched ahead of the big game: 𝗪𝗲’𝗿𝗲 𝗮𝗹𝗹 𝗮 𝗟𝗶𝗹 𝗦𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗲.   In this campaign, we wanted to show that disappointments happen, but that the real strength lies in how we react. Our latest spot with Lil Wayne hints at a big musical announcement, making it a must-watch for hip-hop fans, skincare enthusiasts, and football viewers alike.   With the participation of renowned dermatologist Dr. Muneeb Shah, Cetaphil reinforces its dermatological expertise, because while it can't solve every delicate situation, it can help soothe sensitive skin.   This campaign is a testament to our dedication to every skin story, and we can't wait for you to discover it!   #Cetaphil #SensitiveSkin #SuperBowl #LilWayne #LilSensitive #PassTheCetaphil #SeatToFill

It has been a productive whirlwind of activities at our SKIN medical summit in Berlin! We've heard incredible insights from our speakers and attending healthcare professionals on the real-world clinical practice of treating #AtopicDermatitis and #PrurigoNodularis.    Especially fruitful have been our peer-to-peer exchange sessions where attendees and speakers alike shared valuable learnings and experiences of treating these chronic skin conditions, which can negatively impact patients’ quality of life.    #AdvancingDermatology #SkinSciencebyGalderma Prof. Dr. Bernhard Homey, Chih-ho Hong, Maxwell Sauder, Andreas Wollenberg, Olivier Chambenoit, Chiedzo Mpofu, MD, PhD

We are pleased to share that our initial public offering (IPO) in 2024 has won the EMEA IPO of the Year award from the International Financing Review (IFR). Recognized in IFR’s annual banking and capital markets awards, our listing on the SIX Swiss Exchange nearly a year ago made history as the largest placement volume in Switzerland since 2017 – and one of the largest healthcare IPOs ever. This award and our strong performance are a reflection of the success of our proven Integrated Dermatology Strategy. They also demonstrate our unwavering commitment to meeting the evolving needs of patients and consumers across the full spectrum of dermatology. Thank you to our investors for your continued trust in our management team and your confidence in our growth story. We also thank our teams responsible for this remarkable effort and across Galderma, who contribute every day to our purpose of advancing dermatology for every skin story. #AdvancingDermatology #GALD

Yesterday, amongst the serene snowfall at our Uppsala facility, we were honored to welcome a distinguished delegation of healthcare professionals from Mexico! Their agenda included insightful meetings with our leading scientists, who presented the groundbreaking NASHA and OBT technologies, and a comprehensive tour of our state-of-the-art production facilities. We were delighted to host them at the very heart of innovation and excellence, Galderma Uppsala, the birthplace of Restylane. #SkinSciencebyGalderma #Restylane

We are excited to announce that on February 7, in Berlin, we will be hosting the next installment of our Skin Knowledge Innovation Network (SKIN) initiative which will deep dive into the burden of itch, among other hot topics in atopic dermatitis and prurigo nodularis.     We can’t wait to welcome around 100 healthcare professionals from across the globe for a day of learning and #AdvancingDermatology together! 

Thank you, IMCAS, for an outstanding 2025 edition! It was a pleasure to connect with some of the brightest minds in the aesthetic community. With two symposia, ten posters, a medical session, a masterclass, five Meet the Expert sessions, and an interactive booth, our presence at IMCAS highlighted our cutting-edge innovations in aesthetics. In addition to all the activities, we showcased the latest developments in the impacts of medication-driven weight loss and unveiled new data about Galderma’s latest innovation made with PEARL™ Technology. #AdvancingDermatology #IMCAS2025 #GoBeyondwithPEARL IMCAS

We’re thrilled to announce that the results from our phase IIIb trial on our first ready-to-use liquid treatment developed with our proprietary PEARL™ Technology for the treatment of moderate to severe frown lines, will be presented today at IMCAS World Congress 2025 in Paris. The data from the study reinforce rapid onset from Day 1 and a duration of effect through 6 months. Learn more: https://lnkd.in/exwbJv5p #IMCAS2025 #AdvancingDermatology #SkinSciencebyGalderma